phase iii-go decis lower olumi
messag report earn includ top bottom line
estim beat see preview small jakafi miss larg outshon
posit ruxolitinib cream vitiligo ph ii trial result see preview ph trial
set initi year end addit announc today longer co-
fund olumi develop order realloc resourc reduc
guidanc reaffirm guidanc item result updat
rais pt
earn consensu small jakafi miss due industry-wid
specif headwind report revenu includ
mileston revenu came higher consensu includ
jakafi sale estim consensu
manag attribut increas coverag gap doughnut hole liabil
expect link howev manag re-affirmed jakafi guidanc
today call indic increas liabil alreadi account
intern project furthermor jakafi saw yoy growth revenu
driven increas increas number myelofibrosi mf polycythemia
vera pv patient respect oper expens estim
street estim manag attribut primarili modifi
 spend alloc result report bottom line beat ep vs
guggenheim estim consensu estim
topic ruxolitinib random ph ii vitiligo meet primari endpoint
initi ph trial confirm random phase ii trial evalu topic
ruxolitinib vitiligo met primari endpoint percentag patient achiev
improv facial-vitiligo area sever index f-vasi manag confirm
full phase ii dataset present medic confer come week
phase program true-v expect initi year current plan
recent preview trial link follow posit top-line data includ
valu indic model increas probabl success po
assumpt topic ruxolitinib vitiligo
longer co-fund olumi develop lower
spend guidanc announc morn plan realloc capit
promis intern project believ could help accomplish growth
diversif result longer co-fund olumi develop
continu receiv royalti global net sale olumi effect
tier base royalti howev increment royalti previous co-
fund calcul base proport post-proof-of-concept develop
co-fund per indic expect decreas time depend lli addit
spend olumi program result decis lower spend
guidanc per account
per non-gaap
pemigatinib cholangiocarcinoma program track data bladder cancer
expect manag confirm remain track file pemigatinib
nda cholangiocarcinoma base top-line
data also expect read addit plan initi
phase frontlin trial pemigatinib cholangiocarcinoma come
month meanwhil evalu pemigatinib bladder cancer continu
enrol continu dose cohort enrol complet expect year end data
continu cohort expect previous guid final
page analyst certif import disclosur
manag reiter plan initi phase ii tumor-agnost trial
pemigatinib year end
graft-versus-host diseas gvhd program track recal jakafi upcom pdufa
date acut gvhd set may previous extend day origin
pdufa feb link reiter approv readi immedi
launch alreadi size structur necessari sale forc potenti
label expans addit manag confirm phase trial
evalu itacitinib newli diagnos agvhd patient complet enrol
result year end furthermor phase trial evalu
itacitinib newli diagnos cgvhd patient current on-going follow initi jan
addit updat includ phase result evalu jakafi
steroid-refractori agvhd phase result evalu jakafi steroid-
refractori cgvhd phase ii geometri result evalu capmatinib novn swx
met-mut non-smal cell lung cancer nsclc nda submiss capmatinib
met-mut nsclc base geometri trial initi clinic program
collabor bispecif mru
model updat reflect earn updat revis non-
reconcili increas po topic ruxolitinib vitligo
follow posit top-line phase ii data reduc olumi spend year
elimin entir futur year well lower olumi royalti rate
time account decreas increment rebat addit adjust
oper expens reflect trend
page analyst certif import disclosur
valu per share previous use probabl adjust free cash flow
project jakafi iclusig olumi itacitinib topic ruxolitinib use discount
rate consist commerci stage biotech compani coverag
termin growth rate pt increas follow increas po topic
ruxolitinib vitiligo decreas spend olumi decreas
increment royalti rate olumi
 regulatori commerci setback
potenti emerg new competitor
lower product sale expect
risk intellectu properti risk manag execut
page analyst certif import disclosur
chang fair valu acquisition-rel conting
interest incom net
unreal gains-to-loss long-term invest
incom tax
balanc sheet statement flow
compani report guggenheim secur llc estim
page analyst certif import disclosur
